articleJournal of Clinical InvestigationJun 25, 2017BRONZE OA

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

Merck & Co., Inc., Rahway, NJ, USA (United States) · University of Washington · +3 more institutions

PubMed
Indexed incrossrefdoajpubmed

Abstract

Programmed death-1-directed (PD-1-directed) immune checkpoint blockade results in durable antitumor activity in many advanced malignancies. Recent studies suggest that IFN-γ is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cells, and baseline intratumoral T cell infiltration may improve response likelihood to anti-PD-1 therapies, including pembrolizumab. However, whether quantifying T cell-inflamed microenvironment is a useful pan-tumor determinant of PD-1-directed therapy response has not been rigorously evaluated. Here, we analyzed gene expression profiles (GEPs) using RNA from baseline tumor samples of pembrolizumab-treated patients. We identified immune-related…

Citation impact

3,827
total citations
FWCI
101.23
Percentile
100%
References
31
Citations per year

Authors

15

Topics & keywords

Keywords
  • Pembrolizumab
  • Immune checkpoint
  • Medicine
  • Tumor microenvironment
  • Immunotherapy
  • Immune system
  • PD-L1
  • Head and neck squamous-cell carcinoma
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.